To the full analysis
Medtronic Plc stock: growth
MDTMedtronic Plc reported $36.36B in revenue for fiscal 2026, up 8.4% on the prior year, up 3.8% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
5.9%
per year from 2007 to 2026, per share 5.3%
Earnings (Annual rate)
2.9%
per year from 2007 to 2026, per share 2.3%
Free cash flow (Annual rate)
4.7%
per year from 2007 to 2026, per share 4.1%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2021 | since 2016 | since 2007 | |
|---|---|---|---|
| Revenue | 3.8% | 2.3% | 5.9% |
| Revenue per share | 4.8% | 3.3% | 5.3% |
| Earnings | 5.9% | 3.1% | 2.9% |
| Earnings per share | 6.9% | 4.1% | 2.3% |
| Free cash flow | 2.1% | 2.7% | 4.7% |
| Free cash flow per share | 3.1% | 3.6% | 4.1% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2007 | $12.3B | $2.8B | $2.29B |
| 2008 | $13.52B | $2.23B | $2.88B |
| 2009 | $14.6B | $2.17B | $3.22B |
| 2010 | $15.82B | $3.1B | $3.5B |
| 2011 | $15.93B | $3.1B | $3.19B |
| 2012 | $16.18B | $3.62B | $3.85B |
| 2013 | $16.59B | $3.47B | $4.43B |
| 2014 | $17.01B | $3.07B | $4.56B |
| 2015 | $20.26B | $2.68B | $4.33B |
| 2016 | $28.83B | $3.54B | $4.17B |
| 2017 | $29.71B | $4.03B | $5.63B |
| 2018 | $29.95B | $3.1B | $3.62B |
| 2019 | $30.56B | $4.63B | $5.87B |
| 2020 | $28.91B | $4.79B | $6.02B |
| 2021 | $30.12B | $3.61B | $4.89B |
| 2022 | $31.69B | $5.04B | $5.98B |
| 2023 | $31.23B | $3.76B | $4.58B |
| 2024 | $32.36B | $3.68B | $5.2B |
| 2025 | $33.54B | $4.66B | $5.19B |
| 2026 | $36.36B | $4.8B | $5.43B |
Revenue by segment
How Medtronic Plc makes its money and how that has shifted. Names are as the company reports them.
- Cardiac and Vascular Group38%
- Neuroscience Group28%
- Medical Surgical24%
- Diabetes Group9%
Figures as a table
| 2022 | 2023 | 2024 | 2025 | 2026 | Share 2026 | |
|---|---|---|---|---|---|---|
| Cardiac and Vascular Group | $11.42B | $11.57B | $11.83B | $12.48B | $13.98B | 38.4% |
| Neuroscience Group | $8.78B | $8.96B | $9.41B | $9.85B | $10.29B | 28.3% |
| Medical Surgical | $9.14B | $8.43B | $8.42B | $8.41B | $8.82B | 24.2% |
| Diabetes Group | $2.34B | $2.26B | $2.49B | $2.76B | $3.11B | 8.6% |
| Total revenue | $31.69B | $31.23B | $32.36B | $33.54B | $36.36B | 100% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2026, period end 24 Apr 2026
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 31 Oct 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.